阿托伐他汀对心房颤动患者血浆脂蛋白相关性磷脂酶A2含量的影响  

Effect of atorvastatin on content of plasma lipoprotein-associated phospholipase A2 in patients with atrial fibrillation

作　　者：于成勇[1] 林荣海[1] 李振光[1] 张道强[1] 

机构地区：[1]潍坊医学院附属文登中心医院检验科,山东文登264400

出　　处：《中国实用医刊》2013年第8期5-7,共3页Chinese Journal of Practical Medicine

摘　　要：目的观察非瓣膜性心房颤动（NVAF）患者血浆脂蛋白相关性磷脂酶A2（LP—PLA2）含量变化的特点及他汀类药物的影响。方法测定169例NVAF患者和124例正常对照者血浆LP—PLA2含量，并进行比较。将169例NVAF患者随机分为NVAF对照组（n=52）、阿司匹林组（n=61）和阿司匹林加阿托伐他汀组（n=56），NVAF对照组不予任何处理，阿司匹林组予阿司匹林（100mg／d），阿司匹林加阿托伐他汀组予阿司匹林（100mg／d）和阿托伐他汀（10mg／d）。检测三组患者治疗前和治疗后3个月、1年时的血浆LP—PLA2含量。结果NVAF患者血浆LP—PLA2为（187±14）ng／ml，显著高于正常对照者的（147±14）ng／ml（P〈0．01）。治疗前及治疗后3个月、1年时，NVAF对照组血浆LP。PLA2含量分别为（187±14）、（190±16）和（196±16）ng／ml，差异无统计学意义；阿司匹林组LP—PLA2分别为（191±15）、（179±12）和（165±15）ng／ml，治疗后LP—PLA2较治疗前显著下降（P〈0．01）；阿司匹林加阿托伐他汀组LP—PLA2分别为（193±16）、（152±14）和（141±12）ng／ml，治疗后LP—PLA2较治疗前显著下降（P〈0．01），且较阿司匹林组下降更明显（P〈0．01）。结论NVAF患者血浆LP—PLA2含量显著升高。阿司匹林与阿托彼他汀联合应用可更显薯降低血浆LP—PLA2含量。NVAF患者在实施抗栓治疗时可考虑加用他汀类药物。Objective To investigate the changes of plasma lipoprotein-associated phospholipase A2 （LP-PLA2） levels in patients with nonvalvular atrial fibrillation （NVAF）and the effects of statins. Methods The changes of plasma LP-PLA2 levels were determined in cases of NVAF who didn＇ t re- cieve any antithrombotic therapy and 124 cases controls, and the difference between them was compared. One hundred and sixty-nine NVAF patients were randomly divided into three groups： 52 cases in NVAF control group, 61 cases in aspirin group and 56 cases in aspirin combined with atorvastatin group. Pa- tients in NVAF control group didn＇t recieve any treatment, the aspirin group was given aspirin 100 ng/d, and the aspirin combined with atorvastatin group was given aspirin 100 mg/d ＋ atorvastatin 10 mg/d. The content of plasma LP-PLA2 levels were determined by ELISA among the three groups before treatment and 3 months, 1 year after treatment. Results LP-PLA2 levels were significantly increased in NVAF group[ （187 ± 14） ng/L], compared with controls[ （147 ±14）ng/L] （ P 〈 0.01）. Before treatment, 3 months and 1 year after treatment, the content of plasma LP-PLA2 levels were （ 187 ±14）, （190 ±16）, （196 ±16） ng/L in NVAF group respectively, the difference had no statistical significance（ P 〉0.05）. The content of plasma LP-PLA2 levels were （191± 15）, （179 ±12）, （165 ±15） ng/L in aspirin group respectively, and the LP-PLA2 levels were significant decreased after treatment, compared with brfore treatment（ P 〈0.01 ） ; The content of plasma LP-PLA2 levels were （193 ±16）, （152 ±14）, （141 ±12） ng/L in aspirin combined with atorvastatin group respectively, the LP- PLA2 levels were significant decreased after treatment, compared with before treatment（ P 〈0.01 ）, and it was significantly decreased than that in aspirin group （ P 〈 0.01 ）. Conclusions The plasma LP- PLA2 levels were significantly elevated in NVAF. The content of plasma LP-PLA2 levels were

关 键 词：心房颤动 脂蛋白相关性磷脂酶A2 缺血性卒中 阿托伐他汀 

分 类 号：R541.75[医药卫生—心血管疾病]